Turnbaugh:Research: Difference between revisions
(→Press) |
No edit summary |
||
| Line 3: | Line 3: | ||
<!-- | <!-- | ||
==Key Questions== | ==Key Questions== | ||
--> | --> | ||
== | ==Inactivation of cardiac drug by gut microbes== | ||
We are using cell culture, mass spectrometry, and studies in gnotobiotic mice (germ-free and colonized) to determine the mechanism of reduction of digoxin and other cardiac glycosides by members of the gut microbiota, and to determine whether or not it is possible to limit this reaction in vivo. | |||
==Single cell methods for analyzing microbial physiology and gene content== | |||
We are using flow cytometry and microfluidics to analyze complex microbial communities collected from the human gut at single cell resolution. These techniques allow us to determine the baseline physiology, activity, and gene content of gut microbes, and how these factors are shaped by clinically relevant perturbations, i.e. exposure to host-targeted drugs and antibiotics. | |||
==The role of diet and surgery in shaping the gut microbiome and host metabolic outcomes== | |||
We are studying how Roux-en-Y gastric bypass surgery re-shapes the gut microbiota, and to what degree these changes contribute to the metabolic outcomes of surgery (in collaboration with Lee Kaplan group at Mass General Hospital). We are also performing experiments on the role of diet in shaping gut microbial ecology. | |||
==Data== | ==Data== | ||
See Gordon lab website [http://gordonlab.wustl.edu/SuppData.html Supplementary Data] | Data can be analyzed in [http://metagenomics.anl.gov MGRAST]<br> | ||
Raw datasets are available from [http://www.ncbi.nlm.nih.gov/geo/ GEO] and [http://www.ncbi.nlm.nih.gov/sra NCBI-SRA]<br> | |||
See Gordon lab website for previous manuscript supporting information [http://gordonlab.wustl.edu/SuppData.html Supplementary Data] | |||
==Press== | ==Press== | ||
Revision as of 07:08, 18 October 2012
Inactivation of cardiac drug by gut microbes
We are using cell culture, mass spectrometry, and studies in gnotobiotic mice (germ-free and colonized) to determine the mechanism of reduction of digoxin and other cardiac glycosides by members of the gut microbiota, and to determine whether or not it is possible to limit this reaction in vivo.
Single cell methods for analyzing microbial physiology and gene content
We are using flow cytometry and microfluidics to analyze complex microbial communities collected from the human gut at single cell resolution. These techniques allow us to determine the baseline physiology, activity, and gene content of gut microbes, and how these factors are shaped by clinically relevant perturbations, i.e. exposure to host-targeted drugs and antibiotics.
The role of diet and surgery in shaping the gut microbiome and host metabolic outcomes
We are studying how Roux-en-Y gastric bypass surgery re-shapes the gut microbiota, and to what degree these changes contribute to the metabolic outcomes of surgery (in collaboration with Lee Kaplan group at Mass General Hospital). We are also performing experiments on the role of diet in shaping gut microbial ecology.
Data
Data can be analyzed in MGRAST
Raw datasets are available from GEO and NCBI-SRA
See Gordon lab website for previous manuscript supporting information Supplementary Data
Press
Biotechniques piece on microfluidics
Harvard Gazette write-up on the Turnbaugh lab
Systems Biology Paper out in PNAS
Science Podcast on detecting novel associations
National Public Radio spot 2009
National Public Radio spot 2006
Nature Podcast transcript 2006
